2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. 상품명 CAS No. Purity 화학구조
  • HY-123203
    CP-608039 331727-55-0 98%
    CP-608039 is a potent and selective adenosine A3 receptor agonist. CP-608039 can be used for ischemic myocardial injury research.
    CP-608039
  • HY-123254
    CCG-224406 1870843-22-3 98%
    CCG-224406 is a selective G protein-coupled receptor kinase 2 (GRK2) inhibitor with the IC50 values of 13 nM, greater than 700-fold selectivity over other GRK subfamilies, and no inhibition of ROCK1. CCG-224406 can be used for study of heart failure.
    CCG-224406
  • HY-123255
    BSc2118 863924-64-5 98%
    BSc2118 is a 20S proteasome inhibitor with an IC50 of approximately 50 nM. BSc2118 induces G2/M phase cell cycle arrest and apoptosis in myeloma cells, inhibits cytoprotective autophagy, and suppresses tumor angiogenesis. BSc2118 reduces MMP9 activity, promotes angioneurogenesis, and alleviates recombinant tissue-type plasminogen activator-induced cerebral toxicity. BSc2118 is applicable to studies related to cerebral ischemia and multiple myeloma.
    BSc2118
  • HY-123268
    Ro 363 74513-77-2 98%
    Ro 363, an effective inotropic stimulant, is a potent and highly selective β1-adrenoceptor agonist. RO 363 is a cardiovascular modulator that reduces diastolic blood pressure and pronounces increases in myocardial contractility.
    Ro 363
  • HY-123293
    UK 34787 72818-36-1 98%
    UK 34787 is a selective thromboxane synthetase inhibitor with little or no activity against cyclooygenase or prostacyclin synthetase.
    UK 34787
  • HY-123309
    Tilnoprofenic acid 52549-42-5 98%
    Tilnoprofenic acid (Y-9223) is a Y-23023 metabolite, cyclo-oxygenase inhibitor. Tilnoprofenic acid inhibits IL-6 production. Tilnoprofenic acid can be used in the research of blood disorders.
    Tilnoprofenic acid
  • HY-123322
    PF-184298 813447-40-4 98%
    PF-184298 is a dual serotonin/noradrenaline reuptake inhibitor with IC50 of 6 nM and 21 nM, respectively.
    PF-184298
  • HY-123353
    Neladenoson dalanate 1239309-58-0 98%
    Neladenoson dalanate (Neladenoson bialanate; BAY-1067197) is a orally active agonist precursor of partial Adenosine A1 Receptor. Neladenoson dalanate has a good pharmacokinetic and safety profile, can be used for the chronic heart diseases.
    Neladenoson dalanate
  • HY-123368
    Zolertine hydrochloride 7241-94-3 98%
    Zolertine hydrochloride is an α-adrenoceptor antagonist with a pKi of 6.81 in rat liver (α1B-adrenoceptors) and 6.35 in rabbit liver (α1A-adrenoceptors) membranes.
    Zolertine hydrochloride
  • HY-123384
    KR30031 205535-74-6 98%
    KR30031, a Verapamil (HY-14275) analog, is an orally active P-glycoprotein (P-gp) inhibitor. KR30031 enhances the cytotoxicity of anticancer agents by inhibiting P-gp with fewer cardiovascular adverse effects. KR30031 can be used to study multidrug resistance (MDR) reversal in cancer.
    KR30031
  • HY-123400
    Samixogrel 133276-80-9 98%
    Samixogrel is an inhibitor of thromboxane A2 receptor and thromboxane synthesis.
    Samixogrel
  • HY-123427
    Transcainide 88296-62-2 98%
    Transcainide (R 54718) is an orally active antiarrhythmic agent.
    Transcainide
  • HY-123445
    AZD7009 864368-79-6 98%
    AZD7009 is a novel antiarrhythmic agrnt. AZD7009 inhibits hKv1.5 and hKv4.3/hKChIP2.2 currents with IC50s of 27.0 and 23.7 muM, respectively.
    AZD7009
  • HY-123463
    CHF-1255 146728-52-1 98%
    CHF-1255 is a new aminotetralin. CHF-1255 can be used in the research of heart failure.
    CHF-1255
  • HY-123563
    Metazosin 95549-92-1 99.35%
    Metazosin (Kenosin) is a potent α1 adrenoceptor blocker. Metazosin is an antihypertensive agent lowering blood pressure.
    Metazosin
  • HY-123569
    ISQ-1 hydrochloride 405165-77-7 98%
    ISQ-1 hydrochloride is an isoquinolinone (IKur) blocker with potential atrial arrhythmic activity. ISQ-1 exhibits cardiac electrophysiological characteristics similar to another structurally distinct IKur blocker previously reported from our laboratory.
    ISQ-1 hydrochloride
  • HY-123613
    AGN192093 159359-95-2 98%
    AGN192093 is a thromboxane A2 receptor (TP) agonist (EC50 = 1.3 nM). AGN192093 exhibits potent and selective thromboxane analog activity in rat blood vessels.
    AGN192093
  • HY-123641
    Celikalim 124916-54-7 98%
    Celikalim (Way 120491) is an antihypertensive agent. Celikalim lowers blood pressure through opening potassium channelsin vascular smooth muscle. Celikalim can inhibit white thrombus formation. Celikalim is a potent potassium opener in dog model. Celikalim can be studied in thrombosis-related research.
    Celikalim
  • HY-123657
    RXP 407 237770-41-1 98%
    RXP 407 is a potent and selective Angiotensin-converting Enzyme (ACE) inhibitor with a Ki of 12nM.
    RXP 407
  • HY-123659
    KR-33028 861218-37-3 98%
    KR-33028 is a selective NHE1 inhibitor. KR-33028 reduces hypoxia-induced necrosis and apoptosis in H9c2 cells. KR-33028 inhibits hypoxia-induced increases in cytoplasmic and mitochondrial Ca2+ levels and cytochrome c release. KR-33028 improves cardiac contractility, reduces lactate dehydrogenase release, and increases tissue ATP, creatine phosphate, and glycogen levels. KR-33028 can be used in research on cancers such as cardioblastoma and cardiovascular diseases such as ischemic stroke.
    KR-33028
Cat. No. 상품명 / Synonyms Application Reactivity